Infliximab therapy in pediatric Crohn’s disease: a review

References

• CuffariCInflammatory bowel disease in children: A pediatrician’s perspectiveMinerva Pediatr200658213915716835574
   PubMedGoogle Scholar
• KugathasanSJuddRHHoffmannRGEpidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in wisconsin: A statewide population-based studyJ Pediatr2003143452553114571234
   PubMed Web of Science ®Google Scholar
• HildebrandHFinkelYGrahnquistLChanging pattern of paediatric inflammatory bowel disease in northern stockholm 1990–2001Gut200352101432143412970135
   PubMed Web of Science ®Google Scholar
• GriffithsAMNguyenPSmithCGrowth and clinical course of children with crohn’s diseaseGut19933479399438344582
   PubMed Web of Science ®Google Scholar
• HiwatashiNEnteral nutrition for crohn’s disease in JapanDis Colon Rectum19974010 SupplS48S539378012
   PubMed Web of Science ®Google Scholar
• GriffithsAMOhlssonAShermanPMMeta-analysis of enteral nutrition as a primary treatment of active crohn’s diseaseGastroenterology19951084105610677698572
   PubMed Web of Science ®Google Scholar
• Gonzalez-HuixFde LeonRFernandez-BanaresFPolymeric enteral diets as primary treatment of active crohn’s disease: A prospective steroid controlled trialGut19933467787828314510
   PubMed Web of Science ®Google Scholar
• ThomsenOOCortotAJewellDA comparison of budesonide and mesalamine for active crohn’s disease. international budesonide-mesalamine study groupN Engl J Med199833963703749691103
   PubMed Web of Science ®Google Scholar
• de FranchisROmodeiPRanziTControlled trial of oral 5-amin-osalicylic acid for the prevention of early relapse in crohn’s diseaseAliment Pharmacol Ther19971158458529354191
   PubMed Web of Science ®Google Scholar
• LevineAWeizmanZBroideEA comparison of budesonide and prednisone for the treatment of active pediatric crohn diseaseJ Pediatr Gastroenterol Nutr200336224825212548062
   PubMed Web of Science ®Google Scholar
• MunkholmPLangholzEDavidsenMFrequency of glucocorticoid resistance and dependency in crohn’s diseaseGut19943533603628150347
   PubMed Web of Science ®Google Scholar
• GreenbergGRFeaganBGMartinFOral budesonide for active crohn’s disease. canadian inflammatory bowel disease study groupN Engl J Med1994331138368418078529
   PubMed Web of Science ®Google Scholar
• RutgeertsPLofbergRMalchowHA comparison of budesonide with prednisolone for active crohn’s diseaseN Engl J Med1994331138428458078530
   PubMed Web of Science ®Google Scholar
• CampieriMFergusonADoeWOral budesonide is as effective as oral prednisolone in active crohn’s disease. the global budesonide study groupGut19974122092149301500
   PubMed Web of Science ®Google Scholar
• CandySWrightJGerberMA controlled double blind study of azathioprine in the management of crohn’s diseaseGut19953756746788549944
   PubMed Web of Science ®Google Scholar
• MarkowitzJGrancherKKohnNA multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed crohn’s diseaseGastroenterology2000119489590211040176
   PubMed Web of Science ®Google Scholar
• FeaganBGRochonJFedorakRNMethotrexate for the treatment of crohn’s disease. the north american crohn’s study group investigatorsN Engl J Med199533252922977816064
   PubMed Web of Science ®Google Scholar
• FeaganBGFedorakRNIrvineEJA comparison of methotrexate with placebo for the maintenance of remission in crohn’s disease. north american crohn’s study group investigatorsN Engl J Med2000342221627163210833208
   PubMed Web of Science ®Google Scholar
• BellSJKammMAReview article: The clinical role of anti-TNFalpha antibody treatment in crohn’s diseaseAliment Pharmacol Ther200014550151410792111
   PubMed Web of Science ®Google Scholar
• ReineckerHCSteffenMWitthoeftTEnhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and crohn’s diseaseClin Exp Immunol19939411741818403503
   PubMed Web of Science ®Google Scholar
• NichollsSStephensSBraeggerCPCytokines in stools of children with inflammatory bowel disease or infective diarrhoeaJ Clin Pathol19934687577608408704
   PubMed Web of Science ®Google Scholar
• CornillieFShealyDD’HaensGInfliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with crohn’s diseaseAliment Pharmacol Ther200115446347311284774
   PubMed Web of Science ®Google Scholar
• LugeringASchmidtMLugeringNInfliximab induces apoptosis in monocytes from patients with chronic active crohn’s disease by using a caspase-dependent pathwayGastroenterology200112151145115711677207
   PubMed Web of Science ®Google Scholar
• ten HoveTvan MontfransCPeppelenboschMPInfliximab treatment induces apoptosis of lamina propria T lymphocytes in crohn’s diseaseGut200250220621111788561
   PubMed Web of Science ®Google Scholar
• ScallonBJMooreMATrinhHChimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functionsCytokine1995732512597640345
   PubMed Web of Science ®Google Scholar
• HanauerSBFeaganBGLichtensteinGRMaintenance infliximab for Crohn’s disease: the ACCENT I randomized trialLancet20023591541154912047962
   PubMed Web of Science ®Google Scholar
• ThayuMMarkowitzJEMamulaPHepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for crohn diseaseJ Pediatr Gastroenterol Nutr200540222022215699701
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJRutgeertsPAdalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM studyGastroenterology2007132525517241859
   PubMed Web of Science ®Google Scholar
• RutgeertsPD’HaensGTarganSEfficacy and safety of retreatment with anti-tumor necrosis factor antibody to maintain remission in Crohn’s diseaseGastroenterology199911776176910500056
   PubMed Web of Science ®Google Scholar
• KugathasanSWerlinSLMartinezAProlonged duration of response to infliximab in early but not late pediatric crohn’s diseaseAm J Gastroenterol200095113189319411095340
   PubMed Web of Science ®Google Scholar
• LionettiPBronziniFSalvestriniCResponse to infliximab is related to disease duration in paediatric crohn’s diseaseAliment Pharmacol Ther200318442543112940928
   PubMed Web of Science ®Google Scholar
• BorrelliOBasciettoCViolaFInfliximab heals intestinal inflammatory lesions and restores growth in children with crohn’s diseaseDig Liver Dis200436534234715191204
   PubMedGoogle Scholar
• VeresGBaldassanoRNMamulaPInfliximab therapy in children and adolescents with inflammatory bowel diseaseDrugs200767121703172317683171
   PubMed Web of Science ®Google Scholar
• de RidderLBenningaMATaminiauJAInfliximab use in children and adolescents with inflammatory bowel diseaseJ Pediatr Gastroenterol Nutr200745131417592358
   PubMed Web of Science ®Google Scholar
• BaldassanoRBraeggerCPEscherJCInfliximab (REMICADE) therapy in the treatment of pediatric crohn’s diseaseAm J Gastroenterol200398483383812738464
   PubMed Web of Science ®Google Scholar
• CezardJPNouailiNTalbotecCA prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn diseaseJ Pediatr Gastroenterol Nutr200336563263612717087
   PubMed Web of Science ®Google Scholar
• HyamsJSMarkowitzJWyllieRUse of infliximab in the treatment of crohn’s disease in children and adolescentsJ Pediatr2000137219219610931411
   PubMed Web of Science ®Google Scholar
• LamireauTCezardJPDabadieAEfficacy and tolerance of infliximab in children and adolescents with crohn’s diseaseInflamm Bowel Dis200410674575015626892
   PubMed Web of Science ®Google Scholar
• HyamsJCrandallWKugathasanSInduction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in childrenGastroenterology2007132386387317324398
   PubMed Web of Science ®Google Scholar
• CrandallWHyamsJKugathasanSInfliximab therapy in children with concurrent perianal Crohn disease: observation from REACHJ Pediatr Gastroenterol Nutr20094918319019561542
   PubMed Web of Science ®Google Scholar
• RuemmeleFMLachauxACezardJPEfficacy of infliximab in pediatric Crohn’s disease: a randomized multi-center open-label trial comparing schedule to on demand maintenance therapyInflamm Bowel Dis20091538839419023899
   PubMed Web of Science ®Google Scholar
• HyamsJSLererTGriffithsALong-term outcome of maintenance infliximab therapy in children with Crohn’s diseaseInflamm Bowel Dis20091581682219107783
   PubMed Web of Science ®Google Scholar
• CandonSMoscaARuemmeleFClinical and biological consequences of immunization to infliximab in pediatric crohn’s diseaseClin Immunol20061181111916125467
   PubMed Web of Science ®Google Scholar
• MieleEMarkowitzJEMamulaPHuman antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximabJ Pediatr Gastroenterol Nutr200438550250815097438
   PubMed Web of Science ®Google Scholar
• BaertFNomanMVermeireSInfluence of immunogenicity on the long-term efficacy of infliximab in crohn’s diseaseN Engl J Med2003348760160812584368
   PubMed Web of Science ®Google Scholar
• FriesenCACalabroCChristensonKSafety of infliximab treatment in pediatric patients with inflammatory bowel diseaseJ Pediatr Gastroenterol Nutr200439326526915319627
   PubMed Web of Science ®Google Scholar
• CrandallWVMacknerLMInfusion reactions to infliximab in children and adolescents: Frequency, outcome and a predictive modelAliment Pharmacol Ther2003171758412492735
   PubMed Web of Science ®Google Scholar
• JacobsteinDAMarkowitzJEKirschnerBSPremedication and infusion reactions with infliximab: Results from a pediatric inflammatory bowel disease consortiumInflamm Bowel Dis200511544244615867583
   PubMed Web of Science ®Google Scholar
• VermeireSNomanMVan AsscheGAutoimmunity associated with anti-tumor necrosis factor alpha treatment in crohn‘s disease: A prospective cohort studyGastroenterology20031251323912851868
   PubMed Web of Science ®Google Scholar
• MyersAClarkJFosterHTuberculosis and treatment with infliximabN Engl J Med2002346862362611859881
   PubMed Web of Science ®Google Scholar
• KeaneJGershonSWiseRPTuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agentN Engl J Med2001345151098110411596589
   PubMed Web of Science ®Google Scholar
• VeresGBaldassanoRNMamulaPInfliximab therapy in children and adolescents with inflammatory bowel diseaseDrugs200767121703172317683171
   PubMed Web of Science ®Google Scholar
• ColombelJFLoftusEVJrTremaineWJThe safety profile of infliximab in patients with crohn’s disease: The mayo clinic experience in 500 patientsGastroenterology20041261193114699483
   PubMed Web of Science ®Google Scholar
• KamathBMMamulaPBaldassanoRNListeria meningitis after treatment with infliximabJ Pediatr Gastroenterol Nutr200234441041211930099
   PubMed Web of Science ®Google Scholar
• EsteveMSaroCGonzalez-HuixFChronic hepatitis B reactivation following infliximab therapy in crohn’s disease patients: Need for primary prophylaxisGut20045391363136515306601
   PubMed Web of Science ®Google Scholar
• CezardJPNouailiNTalbotecCA prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn diseaseJ Pediatr Gastroenterol Nutr200336563263612717087
   PubMed Web of Science ®Google Scholar
• LichtensteinGRFeaganBGCohenRDSerious infections and mortality in association with therapies for crohn‘s disease: TREAT registryClin Gastroenterol Hepatol20064562163016678077
   PubMed Web of Science ®Google Scholar
• BianconeLOrlandoAKohnAInfliximab and newly diagnosed neoplasia in crohn’s disease: A multicentre matched pair studyGut200655222823316120759
   PubMed Web of Science ®Google Scholar
• MackeyACGreenLLiangLCHepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel diseaseJ Pediatr Gastroenterol Nutr200744226526717255842
   PubMed Web of Science ®Google Scholar